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Introduction
Invariant NKT cells are a subset of rare but powerful immunomodulatory T cells that are highly conserved between humans and mice 1 . They are selectively activated by glycolipids such as the prototypic ligand alpha-galactosylceramide (GC) presented by CD1d and are characterised by an invariant TCR pairing with a diverse TCR chain (TCRV24J18 and TCRV11 in humans) 1 . iNKT cells comprise two main subsets, CD4+ and CD4-cells, which in humans have distinct cytokine secretion profiles 2 . While the ability of murine iNKT cells to modulate immune responses against pathogens, in autoimmunity and in alloreactivity including experimental acute graft-versus-host disease (aGVHD) is firmly established 3 , the functional role, if any, of human iNKT cells in physiology and disease is ill-defined 4 .
Acute GVHD is the main source of treatment-related morbidity and mortality in patients receiving a T cell-replete allogeneic HSCT. It is caused by alloreactive donor T cells that are activated by host antigen presenting cells (APC) as a result of minor or major histocompatibility antigen disparity between donor and recipient 5;6 and subsequently target recipient tissues such as the skin, liver and gut 6 . The critical role of T cells as effectors of aGVHD is highlighted by the dramatic reduction in the incidence and severity of aGVHD in patients receiving T cell-depleted or syngeneic allografts 7 . Since T cell depletion of the graft is also associated with an increased risk of leukaemia relapse and infections, research has also focused on identifying other cellular components of the graft that impact on the incidence and severity of aGVHD. Indeed, the impact of the graft content of several immune effectors such as T, NK 8 and more recently B cells 9 as well as of the CD4+CD25hiFoxP3+ T regulatory cells (Tregs) 10 ;11 on the risk of aGVHD has been studied extensively.
The role of graft iNKT cells on the risk of aGVHD has not been investigated in humans. By contrast, in murine models, both recipient and donor iNKT cells were shown to effectively protect against experimental aGVHD. In a model involving lymphoablation with total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG), recipient iNKT cells preferentially survive due to radioresistance, secrete IL-4 and thus inhibit aGVHD 12 . In line 4 with these findings, ATG/TLI conditioning was shown to be associated with reduced incidence of aGVHD in humans 13 . Remarkably, iNKT cells in G-CSF-mobilised grafts were shown to protect from experimental aGVHD while enhancing the graft-versus-leukaemia (GVL) effect 14 and in vitro expanded donor iNKT cells alleviate aGVHD in a major histocompatibility complex (MHC) haploidentical setting 15;16 . Recent work also demonstrated the ability of unmanipulated, adoptively transferred donor iNKT cells to protect from experimental aGVHD without prior in vitro expansion 17 .
To directly test whether the protective role of donor iNKT cells shown in pre-clinical models also holds true in clinical allogeneic HSCT, we studied the impact of the dose of graft iNKT cells on the incidence and severity of aGVHD after a T-cell replete allogeneic HSCT from HLA-identical sibling donors.
Patients and Methods
Donors.
The research protocol was approved by the Imperial College Healthcare NHS Trust research ethics committee and all participants gave written informed consent. We analysed the frequency of effector and regulatory lymphocytes in cryopreserved samples of 78 sibling donor, G-CSF-mobilised peripheral blood stem cell (PBSC) grafts used for allogeneic HSCT between 1998 and 2011. In all cases, stem cell mobilisation, collection and storage of the graft were performed according to the same, JACIE-approved standard operating procedures. aGVHD diagnosis and grading criteria were as described 18 . Cells were resuspended in phosphate buffer saline (PBS) plus 0.5% bovine serum albumin.
Flow
Fc blocking reagent (Miltenyi Biotec, Germany) was used to reduce non-specific staining and 4',6-diamidino-2-phenylindole (DAPI) was used for dead cell exclusion. , and a backward stepping procedure was utilised to find the best model. Graft cell subset doses infused were compared between the aGVHD groups using the Mann-Whitney test. Statistical analyses were carried out using the software packages SPSS v19 and R. P values <0.05 were deemed statistically significant.
Results
Frequency distribution of effector and regulatory lymphocytes in G-CSF-mobilised PBSC donor grafts
The frequencies of total, CD4+ and CD4-iNKT cells, CD4+, CD8+ and total T cells, B cells, NK cells as well as Tregs were analysed by multicolour flow-cytometry in 78 normal donor G-CSF-mobilised PBSC grafts (Suppl Figure 1) . In addition, the frequency of CD3+CD161+ regulatory T cells previously shown to be enriched in non-invariant, CD1d-restricted T cells that can suppress in vitro alloreactivity was determined 21 . The frequencies and the absolute doses of the graft cell populations infused to patients at the time of peripheral blood stem cell transplant (PBSCT) are shown in Table 1 . A striking feature of iNKT cells that distinguishes them from the other cellular components is their distinct skewed distribution pattern and dramatic (up to a 1000-fold) variation of their frequency (Suppl Figure 2 and Table 1 ). This variation is independent of sex and age (Suppl Figure 3) .
Finally, there was no correlation between frequency of iNKT cells with that of Tregs or any of the other T cell subsets (data not shown).
Patient characteristics
To analyse the impact of clinical variables and graft cellular components on aGVHD, out of the 78 studied donors we selected a cohort of 57 consecutive donor-recipient pairs in whom a G-CSF mobilised PBSC graft was used for a T cell-replete, sibling HLA-identical, either myeloablative (n=41) or reduced intensity conditioning (n=16) allogeneic HSCT for haematological malignancies. These included chronic myeloid leukaemia (CML, n=18), acute myeloid leukaemia (AML, n=23), acute lymphoblastic leukaemia (ALL, n=6), myelodysplastic syndrome (MDS, n=5), multiple myeloma (MM, n=2), myelofibrosis (n=2)
and Sezary syndrome (n=1) (Suppl Table 1 ). None of the 57 patients received either ATG or alemtuzumab in the preparative regimen. aGvHD prophylaxis was cyclosporine-A plus methotrexate. The inclusion criteria aimed at minimising confounding factors that would mask the effect of graft iNKT cells on the incidence and severity of aGVHD. Therefore, T cell-depleted HSCT were not included.
PBSC graft content and acute graft-versus-host disease
Since iNKT cells uniquely amongst the lymphocyte subsets showed a distinct skewed distribution pattern we predicted that in conjunction with the marked variability of their frequency in PBSC grafts, iNKT cell graft dose could be an important determinant of the incidence and severity of aGVHD.
The cumulative incidence of grade II-IV aGVHD for the 57 patients receiving a G-CSFmobilised PBSC, T cell-replete, HLA-identical, sibling donor allograft was 47.3% at 180 days post-transplant (Fig 1A) . The impact of the dose of the principal cellular components of the PBSC graft and of clinical variables ( Table 2 ) previously shown to impact on the incidence of grade II-IV aGVHD [22] [23] [24] [25] [26] were analysed.
In univariate analyses, total iNKT, CD4+ iNKT and CD4-iNKT cell doses and the diagnosis of CML were significantly (p<0.05) associated with grade II-IV aGVHD (Figure 1B-D and Table 2 ). The cumulative incidence of grade II-IV aGVHD at 180 days post HSCT for recipients receiving cell doses below and above the median for total iNKT cells was 64.3%
vs 31% (p=0.014), for CD4+ iNKT cells 67.5% vs 27.6% (p=0.002), and for CD4-iNKT cells 71.4% vs 24.2% (p=0.0008). In line with these results, iNKT cell doses were the only graft variables that were statistically different between patients who subsequently developed grade II-IV and those with grade 0-I aGVHD (Suppl Table 2 ). Unlike iNKT cells, graft Treg dose did not predict grade II-IV aGVHD-a similar cumulative incidence of aGVHD was found in patients receiving cell doses below and above the median (50% vs 45%, p=0.6; Table 2 ).
Several clinical variables affecting the risk for aGVHD such as sibling versus unrelated donor, HLA disparities, stem cell source and prophylaxis regimen including the use of ATG or aletuzumab were not relevant to our cohort of patients. Upon univariate analysis of other clinical variables previously shown to confer an increased risk of grade II-IV aGVHD in sibling stem cell transplants, including recipient and donor age, use of TB,I sex mismatched transplants and diagnosis of CML [22] [23] [24] [25] [26] , only the latter was found to impact on the occurrence of aGVHD (Table 2 ). Specifically, the cumulative incidence of grade II-IV aGVHD for patients with a diagnosis of CML was 61% compared with 41% for other malignancies (p=0.038).
Following multivariate regression analysis, CD4-iNKT cell dose and CML diagnosis were the only independent factors associated with the occurrence of grade II-IV aGVHD (Table 3) . A low CD4-iNKT cell dose was associated with a relative risk (RR) of grade II-IV aGVHD of 4.27 (p=0.0023; 95% CI: 1.68-10.85), while diagnosis of CML conferred a RR of 2.54 (p=0.036; 95% CI: 1.06-6.04). Unlike aGVHD, we found no association between the iNKT cell dose infused and occurrence of moderate to severe chronic GVHD (data not shown).
Function of CD4-iNKT cells in the in vitro alloresponse
To directly show that human iNKT cells are able to inhibit the alloresponse, as shown in murine studies in which GC-expanded donor iNKT cells ameliorate experimental By studying a larger cohort than in previous reports 27 we confirmed that graft iNKT cells are as rare and as variable in their frequency as peripheral blood iNKT cells and found that in terms of frequency, they are the most variable amongst all other graft cellular components.
Consequently, for patients who would otherwise receive comparable doses of other cell types, there is a higher probability that they would receive considerably different doses of iNKT cells. Given the efficacy of donor iNKT cells in controlling murine aGVHD, we anticipated that higher doses of iNKT cells might also be protective in the clinical setting.
Indeed, univariate analysis demonstrated the unique effect of total iNKT cells and subsets in predicting aGVHD. Multivariate analysis showed that a low median dose of CD4-iNKT cells was the only variable associated with grade II-IV aGVHD with a relative risk of 4.27. This level of risk prediction is one of the highest reported either for clinical parameters or graft cellular components and suggests a powerful influence of iNKT cell dose on the incidence and severity of aGVHD.
In contrast to previous reports 22 , clinical variables such as recipient age and conditioning regimen were not significant determinants of aGVHD in our study. This is very likely due to the small effect that each of these parameters exerts on the risk of aGVHD (generally RR <2) which our study was underpowered to detect. In line with previous reports 22 , CML diagnosis was associated with higher risk of aGVHD (Table 2 ) than other haematological malignancies.
To determine whether graft cellular subsets other than T cells might predict for the occurrence of aGVHD, the frequencies and contents of other effector and regulatory lymphocyte subsets have been intensively studied. In general, the reported effects of NK protection from aGVHD in vivo, this effect was more consistently observed with CD4-iNKT cells, which in a contact-dependent manner displayed direct cytotoxicity against CD1d-expressing mature myeloid DC. Furthermore, we previously showed that iNKT cells, despite the non-polymorphic nature of CD1d, can display alloreactivity, an effect that requires CD1d and invariant TCR interaction but is instructed by activating KIR interacting with yet to be identified APC ligands 34 . In this regard, iNKT cells resemble NK cells which in the context of donor-recipient KIR mismatch are activated and exert a selective GVL effect 35 .
We therefore propose that one possible mechanism for the protective effect of iNKT cells might involve donor CD4-iNKT cells interacting with host APC, the cells that orchestrate aGVHD in secondary lymphoid organs 36 . This interaction would lead to activating KIRdependent iNKT cell activation, followed by perforin-mediated cytolysis of APC.
In the clinical setting, enhancing the iNKT cell dose by adding-back either ex vivo selected or in vitro expanded iNKT cells to iNKT cell-poor grafts might constitute a novel strategy for prevention of moderate to severe aGVHD. To this end, clinical grade protocols for iNKT cell selection and expansion are under development 37 .
In conclusion, this study shows that the dose of iNKT, and in particular of CD4-iNKT cells delivered with the PBSC graft in the context of HLA-identical T cell-replete allogeneic HSCT, is a significant determinant of the incidence and severity of aGVHD and provides a basis for developing new strategies for its prevention. 
